Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1958 1
1971 2
1972 1
1973 2
1974 1
1976 2
1977 1
1978 1
1979 1
1981 1
1984 1
1986 2
1988 1
1990 1
1991 1
1992 1
1993 2
1994 1
1995 1
1997 6
1998 6
1999 5
2000 5
2001 3
2002 4
2003 10
2004 9
2005 9
2006 20
2007 21
2008 23
2009 10
2010 20
2011 22
2012 28
2013 18
2014 22
2015 10
2016 9
2017 5
2018 20
2019 9
2020 23
2021 27
2022 18
2023 14
2024 13
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

374 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free PMC article. Clinical Trial.
Letter to the editor.
Siemer CP, Iyengar TM, Crockett CJ, Schlesinger JJ. Siemer CP, et al. Langenbecks Arch Surg. 2022 Dec;407(8):3867-3868. doi: 10.1007/s00423-022-02616-3. Epub 2022 Jul 26. Langenbecks Arch Surg. 2022. PMID: 35879622 No abstract available.
What makes functional amyloids work?
Siemer AB. Siemer AB. Crit Rev Biochem Mol Biol. 2022 Aug;57(4):399-411. doi: 10.1080/10409238.2022.2113030. Epub 2022 Aug 23. Crit Rev Biochem Mol Biol. 2022. PMID: 35997712 Free PMC article. Review.
Robust estimation of bacterial cell count from optical density.
Beal J, Farny NG, Haddock-Angelli T, Selvarajah V, Baldwin GS, Buckley-Taylor R, Gershater M, Kiga D, Marken J, Sanchania V, Sison A, Workman CT; iGEM Interlab Study Contributors. Beal J, et al. Commun Biol. 2020 Sep 17;3(1):512. doi: 10.1038/s42003-020-01127-5. Commun Biol. 2020. PMID: 32943734 Free PMC article.
[Robot-assisted kidney transplantation].
Zeuschner P, Siemer S, Stöckle M. Zeuschner P, et al. Urologe A. 2020 Jan;59(1):3-9. doi: 10.1007/s00120-019-01085-9. Urologe A. 2020. PMID: 31832746 German.
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.
Bergmann L, Albiges L, Ahrens M, Gross-Goupil M, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suarez C, Maroto P, Grünwald V, Oosting SF, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Haanen JB; Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). Bergmann L, et al. Ann Oncol. 2025 Jul;36(7):796-806. doi: 10.1016/j.annonc.2025.03.016. Epub 2025 Apr 1. Ann Oncol. 2025. PMID: 40180121 Free article. Clinical Trial.
Correlation between estimated fetal weight and weight at birth in infants with gastroschisis and omphalocele.
Boute T, Rizzo G, Mappa I, Makatsariya A, Toneto BR, Moron AF, Rolo LC. Boute T, et al. J Matern Fetal Neonatal Med. 2022 Aug;35(16):3070-3075. doi: 10.1080/14767058.2020.1808615. Epub 2020 Aug 19. J Matern Fetal Neonatal Med. 2022. PMID: 32814485
As a result of reduced abdominal circumference, fetal weight may be underestimated, which could affect prenatal management. Siemer et al. proposed a formula without the use of abdominal circumference, but it is not used in our protocols yet. OBJECTIVES: Our aim was to eval …
As a result of reduced abdominal circumference, fetal weight may be underestimated, which could affect prenatal management. Siemer et …
Therapists as fixed versus random effects-some statistical and conceptual issues: a comment on Siemer and Joormann (2003).
Crits-Christoph P, Tu X, Gallop R. Crits-Christoph P, et al. Psychol Methods. 2003 Dec;8(4):518-23. doi: 10.1037/1082-989X.8.4.518. Psychol Methods. 2003. PMID: 14664686
The authors disagree with M. Siemer and J. Joormann's assertion that therapist should be a fixed effect in psychotherapy treatment outcome studies. ...If therapist effects are anticipated and either cannot be minimized through standardization or are specifically of interes …
The authors disagree with M. Siemer and J. Joormann's assertion that therapist should be a fixed effect in psychotherapy treatment ou …
Should providers of treatment be regarded as a random factor? If it ain't broke, don't "fix" it: a comment on Siemer and Joormann (2003).
Serlin RC, Wampold BE, Levin JR. Serlin RC, et al. Psychol Methods. 2003 Dec;8(4):524-34. doi: 10.1037/1082-989X.8.4.524. Psychol Methods. 2003. PMID: 14664687
Serlin's analysis of treatment effects in nested designs, M. Siemer and J. Joormann argued that providers of services should be considered a fixed factor because typically providers are neither randomly selected from a population of providers nor randomly assigned to treat …
Serlin's analysis of treatment effects in nested designs, M. Siemer and J. Joormann argued that providers of services should be consi …
374 results